KYV-101 is an investigational CAR T-cell therapy that’s being developed for MG. Administered via a single infusion into the bloodstream, or intravenously, after a short course of chemotherapy, it is designed to lower the levels of immune B-cells and potentially ease disease severity.
Myasthenia gravis guide to clinical trials
Last updated Aug. 6, 2025, by Agata Boxe
Fact-checked by Patrícia Silva, PhD
Although researchers have made progress with therapies for myasthenia gravis (MG), further work is needed to help manage fatigue, and to improve strength, mobility, and quality of life in people with the autoimmune-related disease.
Scientists continue to explore new treatments through clinical trials, which test whether therapies are safe and effective before they are approved by the U.S. Food and Drug Administration (FDA) or other regulatory agencies
Enrolling in an MG clinical trial can give you access to experimental therapies while helping to advance scientific understanding and treatment options. However, it is key to consult your doctor before deciding whether participation is right for you.
What is an MG clinical trial?
A clinical trial is a carefully designed research study that assesses new ways to treat, manage, or monitor diseases such as MG. It is usually done after lab and animal testing.
MG clinical trials may focus on:
- reducing fatigue and improving muscle weakness through medication
- investigating treatments that may reduce autoantibody production
- studying new therapy delivery methods, such as infusion versus oral
- assessing tools to better track MG symptom changes and responses to treatment.
Clinical trials for MG typically follow four phases:
- Phase 1 trials usually test safety and dosage in a small group of participants.
- Phase 2 trials usually evaluate the effectiveness of treatment while continuing to monitor safety.
- Phase 3 trials generally compare the new therapy to a placebo or existing standard treatment in a larger group.
- Phase 4 trials are done after FDA approval to study long-term safety and effectiveness in a real-world setting.
The benefits and risks of MG trials
The severity of your MG symptoms, such as fatigue, muscle weakness, and droopy eyelids, can influence whether you choose to join a clinical trial. However, it is still important to consider both its benefits and risks.
The benefits of MG clinical trials include:
- early access to promising new treatments
- a chance to proactively manage your MG
- an opportunity to contribute to research that could benefit others with MG.
The risks of clinical trials include:
- potential side effects from new or experimental therapies
- a possible lack of improvement or worsening of symptoms
- the possibility of receiving a placebo or standard therapy
- extra time needed for visits, tests, or travel
- costs not covered by insurance or the study sponsor.
Types of MG clinical trials
Clinical trials for MG can explore various treatments, including:
- immunomodulating therapies
- monoclonal antibody-based treatments for MG
- medications designed to improve nerve-muscle communication.
Some trials will address refractory, or hard-to-treat, MG, and involve people who do not respond to approved treatments. Other studies will test the use of imaging, digital tools, or biomarkers to better track disease activity.
Many MG trials enroll people with generalized MG, where the disease causes muscle weakness in varying parts of the body. Others may target other MG types, such as ocular MG, which mostly affects the muscles responsible for controlling eye and eyelid movements.
Where to find MG clinical trials
To learn about MG clinical trials, start by talking to your neurologist. As a specialist, your neurologist may be aware of trials at academic centers, hospitals, or research networks, and can inform you whether you’re eligible.
You can find additional information through online resources.
For information about clinical trials in the United States, you can try these websites:
- ClinicalTrials.gov
- CenterWatch
- Myasthenia Gravis Foundation of America
- National Institutes of Health
- Research Match.
For trials outside the U.S., these websites may be helpful:
- EU Clinical Trials Register
- ISRCTN Registry (UK)
- World Health Organization
- Australian New Zealand Clinical Trials Registry.
What to ask before joining an MG clinical trial
If you’re considering participating in an MG clinical trial, asking questions can help you make an informed decision. Consider compiling a list of questions for your MG doctor, the research team, and even yourself as you learn more about the trial process.
There are certain questions you might ask your MG doctor:
- Am I a good candidate for an MG clinical trial?
- Are you aware of any current clinical trials for MG that would be suitable for my disease type and symptoms?
- Would participating in a trial affect my current treatment plan?
- What are the potential risks and benefits of the trial you may be recommending?
- What would the trial require in terms of treatment, travel, and time commitment?
Other questions can be asked of the research team:
- What kind of treatment will the trial be testing, and why do you think it will work?
- Are there any known side effects, and if so, how can they be managed?
- Does this study involve a placebo or another MG treatment that is already on the market?
- What are the odds of receiving a placebo or another MG therapy versus the new treatment?
- Who will cover the costs of my participation in the trial, and do I need insurance?
Inquiring about costs is especially important. While many trials cover the cost of experimental treatments and related care, some may not. If you’re insured, you can contact your provider to see if the company can cover participation-related expenses.
Finally, consider this list of questions to ask yourself:
- What do I hope to gain from this trial? Are my expectations realistic?
- Am I prepared for potential side effects or the possibility of receiving a placebo?
- Can I manage the time and travel requirements?
- How may participation affect my daily life and mental health?
- Am I prepared to handle the emotional impact if the treatment doesn’t work for me?
Additional information about MG clinical trials
Clinical trials for MG can offer access to new treatments, as well as a way to perhaps more actively engage in your own care. However, trial participation may not be suitable for everyone, so carefully considering the potential benefits and risks is crucial.
Consult your doctor before enrolling, and don’t hesitate to ask questions — your voice and initiative matter for managing MG symptoms and planning your future.
Myasthenia Gravis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Clinical trial news
Discussion
Amgen’s antibody-based therapy inebilizumab reduces the severity of generalized myasthenia gravis (MG), according to top-line data from a Phase 3 clinical trial. Dubbed MINT (NCT04524273), the study showed inebilizumab’s therapeutic efficacy in gMG patients who test positive for self-reactive antibodies against the acetylcholine receptor (AChR) or muscle-specific…
Descartes-08 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via intravenous, or into-the-vein, infusions, it is designed to lower the levels of immune B-cells and potentially ease disease severity.
NMD670 is an investigational oral therapy being developed for MG and a number of rare diseases. The therapy, administered twice daily in the form of oral tablets, is designed to improve nerve-muscle communication and restore muscle function.
Gefurulimab is an experimental therapy being developed for the treatment of generalized MG. Administered in the form of subcutaneous, or under-the-skin, injections that can be self-administered, it is designed to block the activation of the complement system, a part of the immune system that’s thought to be involved in the disease’s autoimmune attacks.
Recent Posts
- Real-world study finds Vyvgart often effective in gMG, but responses vary
- The traitor within: Navigating the internal triggers of myasthenia gravis
- I had to bite my tongue when my twin told me about a risky home project
- In life with MG, even small battles can feel overwhelming
- MDA 2026: CAR T-cell therapy Descartes-08 eases MG symptoms